Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to -$962,000.

  • Tonix Pharmaceuticals Holding's Cash from Investing Activities fell 10588.89% to -$962,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year decrease of 156.39%. This contributed to the annual value of -$120,000 for FY2024, which is 99.59% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Cash from Investing Activities stood at -$962,000 for Q3 2025, which was up 62.11% from -$2.5 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Cash from Investing Activities' 5-year high stood at -$3,000 during Q4 2024, with a 5-year trough of -$24.0 million in Q2 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$626,000 (2023), whereas its average is -$3.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 99.30% in 2024, then plummeted by 10,588.89% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Cash from Investing Activities stood at -$431,000 in 2023, then spiked by 99.30% to -$3,000 in 2024, then plummeted by 10,588.89% to -$962,000 in 2025.
  • Its Cash from Investing Activities was -$962,000 in Q3 2025, compared to -$2.5 million in Q2 2025 and -$6,000 in Q1 2025.